Prostate cancer hijacks the normal prostate's growth regulation program to release the brakes and grow freely, according to Weill Cornell Medicine researchers. The discovery, published Dec. 13 in ...
A poorly characterized protein, historically thought to be a chaperon or enzyme, may actually be a key player in prostate cancer. In a systematic CRISPR screen, scientists from Arc Institute, UCSF, ...
In a new study published in Nature Signal Transduction and Targeted Therapy titled, “Drugging the intrinsically disordered transactivation domain of androgen receptor,” researchers from the University ...
A TTUHSC research team led by Srinivas Nandana, Ph.D., (center) and Manisha Tripathi, Ph.D., (left) recently completed a study focused on uncovering the molecular and signaling mechanisms that drive ...
Prostate cancer hijacks the normal prostate's growth regulation program to release the brakes and grow freely, according to Weill Cornell Medicine researchers. The discovery, published Dec. 13 in ...
First patients dosed in OPTIMAL-e1 Phase 2 study evaluating TLX597-Tx for metastatic hormone-sensitive prostate cancer at St ...
Prostate cancer begins as an androgen-dependent tumor that undergoes clinical regression in response to pharmacological or surgical strategies that reduce testosterone concentration. Despite this ...
Akeega prostate cancer UK approval: the MHRA has licensed Johnson and Johnson's niraparib-abiraterone combination for men ...
Metastatic prostate cancer is cancer that began in the prostate but has spread to other parts of the body. There's no cure, but there are a number of effective treatments you can discuss with a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results